記住我
Research Article
Rhiem K. · Zachariae S. · Waha A. · Grill S. · Hester A. · Golatta M. · van Mackelenbergh M. · Fehm T. · Schlaiß T. · Ripperger T. · Ledig S. · Meisel C. · Speiser D. · Veselinovic K. · Schröder C. · Witzel I. · Gallwas J. · Weber B.H.F. · Solbach C. · Aktas B. · Hahnen E. · Engel C. · Schmutzler R.
Introduction: International guidelines recommend genetic testing for women with familial breast cancer at an expected prevalence of pathogenic germline variants (PVs) of at least 10%. In a study sample of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), we have previously shown that women with TNBC diagnosed before the age of 50 years but without a family history of breast or ovarian cancer (sTNBC) meet this criterion. The present study investigates the PV prevalence in BRCA1, BRCA2 and nine additional can-cer predisposition genes in an extended sTNBC study sample including a cohort of women with a later age at sTNBC diagnosis. Patients and methods: In 1600 women with sTNBC (median age at diagnosis 41 years, range 19-78 years) we investigated the association between age at diagnosis and PV occur-rence in cancer predisposition genes using logistic regression. Results: 260 sTNBC patients (16.2%) were found to have a PV in cancer predisposition genes (BRCA1: n=170 [10.6%]; BRCA2: n=46 [2.9%], other: n=44 [2.8%]). The PV prevalence in women diagnosed between 50 and 59 years (n=194) was 11.3% (22/194). Logistic regression showed a significant increase in PV prevalence with decreasing age at diagnosis (OR 1.41 per 10 years younger age at diagnosis; 95%CI 1.21-1.65; p
The Author(s). Published by S. Karger AG, Basel
Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)